GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis

Marie-Pier Tetreault*, Peter J Kahrilas

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Purpose of Review: Esophageal dysfunction is common in systemic sclerosis (SSc) patients. Limited treatment options are available for scleroderma esophageal disease. Here, we discuss recent updates on the diagnosis, treatment, and characterization that have been made in patients with scleroderma esophageal disease. Recent Findings: In the past few years, novel diagnostic tools have provided insight into esophageal dysmotility in SSc patients. New drugs are being tested and might improve symptoms and quality of life in SSc patients with esophageal dysfunction. Molecular stratification methods have facilitated the identification of molecular signatures in the esophagus of SSc patients. The Friend leukemia integration 1 (Fli1) conditional knockout mouse is the first animal model to report an esophageal phenotype with SSc features. Summary: The clinical presentation in SSc patients with esophageal dysfunction is heterogeneous, complicating diagnosis and management. The improvement of diagnostic tools for esophageal symptoms and dysfunction and the use of molecular approaches in SSc mouse models and patient biopsies offer an opportunity to improve the characterization of SSc esophageal disease, which should help improve management and treatment decisions.

Original languageEnglish (US)
Article number42
JournalCurrent rheumatology reports
Volume21
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

    Fingerprint

Keywords

  • Esophageal reflux monitoring
  • Esophagus
  • Functional luminal imaging probe
  • Impedance
  • Manometry
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology

Cite this